• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Stronger EPS, Ralinepag Progress, and Buybacks Might Change The Case For Investing In United Therapeutics (UTHR)

    Simply Wall St·08/07/2026 11:42:13
    Listen to the news
    • In the past week, United Therapeutics reported Q2 2026 results showing sales of US$783.3 million, a slight year-on-year dip, alongside higher net income of US$333 million and diluted EPS of US$7.27, while completing a US$1.50 billion buyback and highlighting strong phase 3 data plus an FDA filing for ralinepag in pulmonary arterial hypertension.
    • Beyond the quarterly numbers, the combination of robust ralinepag outcomes, New Drug Applications for ralinepag and nebulized Tyvaso, and meaningful share repurchases underscores how United Therapeutics is using its pulmonary pipeline and balance sheet to reinforce earnings power even as headline revenue growth faces competitive pressure.
    • We’ll now examine how the stronger EPS, ralinepag phase 3 success, and FDA filings may reshape United Therapeutics’ investment narrative.

    Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

    United Therapeutics Investment Narrative Recap

    To own United Therapeutics, you need to believe its pulmonary franchise and late‑stage assets can offset competitive pressure in PAH while funding longer‑term bets like organ technologies. The latest quarter reinforces that tension: slightly lower sales alongside higher EPS and a large completed buyback, plus strong ralinepag phase 3 data and FDA filings, sharpen the near term catalyst around regulatory outcomes, while competition in inhaled prostacyclins remains the clearest immediate risk.

    Among recent announcements, the ADVANCE OUTCOMES phase 3 results for ralinepag and the subsequent FDA filing stand out. The study met its primary and key secondary endpoints in PAH, and United Therapeutics has now formally submitted an NDA to the FDA. That filing sits at the heart of the current catalyst stack, because the pulmonary portfolio is still concentrated in a few therapies and any change in the ralinepag regulatory path could materially influence how investors view future earnings resilience.

    But while the pulmonary pipeline looks encouraging, investors should still be aware of how quickly competition and patent exposure around core PAH drugs could...

    Read the full narrative on United Therapeutics (it's free!)

    United Therapeutics' narrative projects $4.5 billion revenue and $1.8 billion earnings by 2029.

    Uncover how United Therapeutics' forecasts yield a $665.23 fair value, a 25% upside to its current price.

    Exploring Other Perspectives

    UTHR 1-Year Stock Price Chart
    UTHR 1-Year Stock Price Chart

    Some of the most cautious analysts were assuming only about 1.2 percent annual revenue growth to roughly US$3.3 billion and 2029 earnings near US$1.4 billion, so compared with the base case they are effectively pricing in much greater pressure on PAH expectations and more risk that heavy R&D spending does not fully pay off, which means this quarter’s ralinepag progress and buyback completion could eventually shift those narratives in very different ways.

    Explore 3 other fair value estimates on United Therapeutics - why the stock might be worth just $658.08!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your United Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.
    • Our free United Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United Therapeutics' overall financial health at a glance.

    Ready For A Different Approach?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.